Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982929 | 0.85 | POLB (0.54) | DRD2POLBPPARGPPARDPPARA | |
| SCHEMBL25268928 | 0.85 | TIPARP (0.52) | TIPARPSIGMAR1 | |
| SCHEMBL31724031 | 0.84 | CHRM2 (0.52) | DRD2POLBPPARGPPARDPPARA | |
| SCHEMBL27233715 | 0.83 | POLB (0.55) | POLBPPARGPPARDPPARATIPARP | |
| SCHEMBL25223832 | 0.83 | TIPARP (0.49) | PPARGPPARDPPARATIPARPCHRM2 | |
| SCHEMBL25261117 | 0.83 | TIPARP (0.55) | TIPARPCHRM2CHRM1SIGMAR1 | |
| SCHEMBL24968158 | 0.82 | SIGMAR1 (0.47) | PPARGPPARDPPARATIPARPCHRM2 | |
| SCHEMBL30080558 | 0.82 | TIPARP (0.52) | TIPARPSIGMAR1 | |
| SCHEMBL25699748 | 0.81 | TIPARP (0.56) | PPARGPPARDPPARATIPARPCHRM2 | |
| SCHEMBL25699673 | 0.81 | CXCR3 (0.45) | DRD2PPARGPPARDPPARATIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | DRD2 4016/4885POLB 197/4885PPARG 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.